1. Home
  2. INVH vs NTRA Comparison

INVH vs NTRA Comparison

Compare INVH & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVH
  • NTRA
  • Stock Information
  • Founded
  • INVH 2012
  • NTRA 2003
  • Country
  • INVH United States
  • NTRA United States
  • Employees
  • INVH N/A
  • NTRA N/A
  • Industry
  • INVH Real Estate
  • NTRA Medical Specialities
  • Sector
  • INVH Finance
  • NTRA Health Care
  • Exchange
  • INVH Nasdaq
  • NTRA Nasdaq
  • Market Cap
  • INVH 19.1B
  • NTRA 18.4B
  • IPO Year
  • INVH 2017
  • NTRA 2015
  • Fundamental
  • Price
  • INVH $33.62
  • NTRA $148.08
  • Analyst Decision
  • INVH Buy
  • NTRA Strong Buy
  • Analyst Count
  • INVH 16
  • NTRA 17
  • Target Price
  • INVH $37.81
  • NTRA $176.65
  • AVG Volume (30 Days)
  • INVH 3.7M
  • NTRA 1.6M
  • Earning Date
  • INVH 04-30-2025
  • NTRA 05-08-2025
  • Dividend Yield
  • INVH 3.45%
  • NTRA N/A
  • EPS Growth
  • INVH N/A
  • NTRA N/A
  • EPS
  • INVH 0.74
  • NTRA N/A
  • Revenue
  • INVH $2,590,497,000.00
  • NTRA $1,696,911,000.00
  • Revenue This Year
  • INVH $5.31
  • NTRA $15.33
  • Revenue Next Year
  • INVH $3.78
  • NTRA $18.50
  • P/E Ratio
  • INVH $45.44
  • NTRA N/A
  • Revenue Growth
  • INVH 7.29
  • NTRA 56.75
  • 52 Week Low
  • INVH $29.37
  • NTRA $83.13
  • 52 Week High
  • INVH $37.80
  • NTRA $183.00
  • Technical
  • Relative Strength Index (RSI)
  • INVH 54.09
  • NTRA 50.83
  • Support Level
  • INVH $29.37
  • NTRA $125.38
  • Resistance Level
  • INVH $32.45
  • NTRA $152.66
  • Average True Range (ATR)
  • INVH 1.22
  • NTRA 8.82
  • MACD
  • INVH -0.00
  • NTRA 1.47
  • Stochastic Oscillator
  • INVH 74.17
  • NTRA 82.19

About INVH Invitation Homes Inc.

Invitation Homes owns a portfolio of nearly 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: